AU2012281042B2 - Combination ALS therapy - Google Patents

Combination ALS therapy

Info

Publication number
AU2012281042B2
AU2012281042B2 AU2012281042A AU2012281042A AU2012281042B2 AU 2012281042 B2 AU2012281042 B2 AU 2012281042B2 AU 2012281042 A AU2012281042 A AU 2012281042A AU 2012281042 A AU2012281042 A AU 2012281042A AU 2012281042 B2 AU2012281042 B2 AU 2012281042B2
Authority
AU
Australia
Prior art keywords
riluzole
subject
administered
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012281042A
Other languages
English (en)
Other versions
AU2012281042A1 (en
Inventor
Jesse Cedarbaum
Fady Malik
John Mao
Andrew A. Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2012281042A1 publication Critical patent/AU2012281042A1/en
Assigned to CYTOKINETICS, INC. reassignment CYTOKINETICS, INC. Request for Assignment Assignors: CEDARBAUM, JESSE, CYTOKINETICS, INC., MALIK, FADY, MAO, JOHN, WOLFF, ANDREW
Application granted granted Critical
Publication of AU2012281042B2 publication Critical patent/AU2012281042B2/en
Priority to AU2016244263A priority Critical patent/AU2016244263A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012281042A 2011-07-13 2012-07-12 Combination ALS therapy Ceased AU2012281042B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016244263A AU2016244263A1 (en) 2011-07-13 2016-10-13 Combination ALS therapy

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US61/507,381 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US61/544,533 2011-10-07
US201261637759P 2012-04-24 2012-04-24
US201261637770P 2012-04-24 2012-04-24
US61/637,759 2012-04-24
US61/637,770 2012-04-24
US201261646699P 2012-05-14 2012-05-14
US61/646,699 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016244263A Division AU2016244263A1 (en) 2011-07-13 2016-10-13 Combination ALS therapy

Publications (2)

Publication Number Publication Date
AU2012281042A1 AU2012281042A1 (en) 2014-01-30
AU2012281042B2 true AU2012281042B2 (en) 2016-07-14

Family

ID=47506929

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012281042A Ceased AU2012281042B2 (en) 2011-07-13 2012-07-12 Combination ALS therapy
AU2016244263A Abandoned AU2016244263A1 (en) 2011-07-13 2016-10-13 Combination ALS therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016244263A Abandoned AU2016244263A1 (en) 2011-07-13 2016-10-13 Combination ALS therapy

Country Status (16)

Country Link
US (1) US10272082B2 (OSRAM)
EP (1) EP2731611B1 (OSRAM)
JP (2) JP6145946B2 (OSRAM)
KR (1) KR101951220B1 (OSRAM)
CN (2) CN109316480A (OSRAM)
AU (2) AU2012281042B2 (OSRAM)
BR (1) BR112014000742A2 (OSRAM)
CA (1) CA2849213A1 (OSRAM)
EA (2) EA028060B1 (OSRAM)
HK (1) HK1197178A1 (OSRAM)
IL (1) IL230391B (OSRAM)
IN (1) IN2014DN00200A (OSRAM)
PH (1) PH12014500094A1 (OSRAM)
SG (1) SG10201605707UA (OSRAM)
WO (1) WO2013010015A2 (OSRAM)
ZA (1) ZA201400236B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
US20170042890A1 (en) * 2014-04-29 2017-02-16 Cytokinetics, Inc. Methods of reducing decline in vital capacity
ES2751300T3 (es) * 2014-11-21 2020-03-31 Biohaven Therapeutics Ltd Formulación sublingual de riluzol
EA201791110A1 (ru) * 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CA3018635C (en) 2016-03-25 2023-09-26 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2021055890A1 (en) 2019-09-20 2021-03-25 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
IT1156732B (it) 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
ES2213611T3 (es) 1999-10-08 2004-09-01 Grunenthal Gmbh Derivados biciclicos de imidazo-3-il-amina.
JP2003511456A (ja) 1999-10-08 2003-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二環状イミダゾ−５−イル−アミン誘導体
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005013894A2 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
JP2007521296A (ja) 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
EP1694323A4 (en) 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1796467A4 (en) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006088836A2 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
WO2008016648A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
DK2583970T3 (en) 2006-08-02 2015-11-16 Cytokinetics Inc Certain chemical entities, compositions, and methods comprising imidazopyrimidines
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
WO2008121333A1 (en) 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7989469B2 (en) 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
EP2323691A2 (en) * 2008-07-11 2011-05-25 Glaxo Group Limited Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Ｍｌｋ阻害剤および使用方法
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
RU2012101792A (ru) 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
US20150065525A1 (en) 2012-04-02 2015-03-05 Cytokinetics, Inc. Methods for improving diaphragm function
SG11201406359TA (en) 2012-04-11 2014-11-27 Cytokinetics Inc Improving resistance to skeletal muscle fatigue
US20170042890A1 (en) 2014-04-29 2017-02-16 Cytokinetics, Inc. Methods of reducing decline in vital capacity

Also Published As

Publication number Publication date
PH12014500094A1 (en) 2014-03-17
US20140243344A1 (en) 2014-08-28
AU2016244263A1 (en) 2016-11-03
AU2012281042A1 (en) 2014-01-30
EA201791043A1 (ru) 2017-09-29
WO2013010015A3 (en) 2014-05-15
KR20140074270A (ko) 2014-06-17
KR101951220B1 (ko) 2019-02-22
CA2849213A1 (en) 2013-01-17
ZA201400236B (en) 2014-10-29
EA201490011A1 (ru) 2014-08-29
HK1197178A1 (en) 2015-01-09
US10272082B2 (en) 2019-04-30
WO2013010015A2 (en) 2013-01-17
IN2014DN00200A (OSRAM) 2015-06-05
CN109316480A (zh) 2019-02-12
JP2014520856A (ja) 2014-08-25
NZ619924A (en) 2016-02-26
SG10201605707UA (en) 2016-09-29
JP2017128610A (ja) 2017-07-27
EP2731611B1 (en) 2019-09-18
EP2731611A2 (en) 2014-05-21
IL230391B (en) 2019-03-31
CN104039148A (zh) 2014-09-10
JP6145946B2 (ja) 2017-06-14
BR112014000742A2 (pt) 2016-08-23
EP2731611A4 (en) 2015-02-18
EA028060B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
AU2012281042B2 (en) Combination ALS therapy
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
EP4114466B1 (en) Treatment of pain and vasoconstriction
EP2646031B9 (en) Increasing drug bioavailability in naltrexone therapy
CA3075719A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
US20200323817A1 (en) Methods and compositions for treatment of alzheimer's disease and other neurodegenerative disorders
JP2022518944A (ja) 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法
EP2768481A1 (en) Compositions for reduction of side effects
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
JP6420923B1 (ja) 医薬
NZ619924B2 (en) Combination als therapy
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
MX2014000455A (es) Terapia de combinacion para esclerosis lateral amiotrofica.
JP6860984B2 (ja) 脊髄小脳変性症における運動失調の治療剤の投与レジメン
US20230172895A1 (en) Methods of treating or preventing organophosphorus poisoning
EP2482658B1 (en) Methods and compositions for treatment of raynaud's phenomenon
Menezes et al. Experimental pharmacological agents in the management of Parkinson’s disease
WO2016208045A1 (ja) 脊髄小脳変性症における運動失調の治療剤の投与レジメン

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYTOKINETICS, INC.

Free format text: FORMER APPLICANT(S): MAO, JOHN; CYTOKINETICS, INC.; MALIK, FADY; CEDARBAUM, JESSE; WOLFF, ANDREW

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired